Screening for breast cancer in men has increased over time, with high sensitivity and specificity for mammographic screening.
Healthcare professionals are being advised to monitor patients regularly for pulmonary symptoms indicative of ILD and/or pneumonitis, including hypoxia, cough, dyspnea, and interstitial infiltrates on radiologic exams.
Maintaining full doses of chemo especially important early in the treatment course.
Risk for death from other causes much higher than risk for breast cancer death with increasing comorbidity, age.
Offer risk-reducing meds to women at higher risk for breast cancer, low risk for adverse medication effects.
High prevalence of pathogenic/likely pathogenic variants supports wider testing.
Some excess risk persists for >10 years after ceasing therapy; magnitude varies with duration of use.
In this retrospective study, researchers sought to determine the survival impact of reductions in total cumulative dose and early vs late dose reductions of third-generation adjuvant chemotherapy regimens in patients with early-stage breast cancer.
But counseling not recommended for women without personal, family history, ancestry associated with BRCA mutations.
The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech).
Concurrent use of AI system improves cancer detection, reduces reading time and recall rate.
Total number of CTCs, rather than the presence of clusters, may be more prognostically important.
Findings for women undergoing additional plastic or gynecological procedure at time of breast cancer surgery.
Survivors of NHL should be offered genetic counseling.
Emerging overall survival data show a benefit of this type of drug across a variety of patient subgroups.
Time interval from diagnosis to surgery has largest impact on time from diagnosis to chemo initiation.
Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) have been made available by Amgen and Allergan.
Researchers compared the development of specific CVD risk factors in postmenopausal women who survived breast cancer and women without history of breast cancer.
Physicians need more education about breast density and breast cancer screening.
The risk of breast implant-associated anaplastic large cell lymphoma may be higher than previously reported for women who receive textured implants, according to researchers.